NMN was the breakthrough that changed longevity science. NMNH is what comes next. More direct. More potent. Clinically shown to elevate NAD⁺ levels 3× faster — and now available outside the lab for the first time.
NMNH (β-Dihydronicotinamide Mononucleotide) is a structurally distinct and more bioavailable form of the NAD⁺ precursor molecule. Where NMN requires enzymatic conversion steps to raise NAD⁺, NMNH takes a more direct route — resulting in significantly faster and greater NAD⁺ elevation.
Age Factory™ sources NMNH exclusively as UthPeak™ — the world's first commercially certified NMNH ingredient, manufactured to pharmaceutical-grade purity standards.
| Compound | NAD⁺ Elevation | Speed | Pathway |
|---|---|---|---|
| NMN | High | Standard | Indirect (NMN→NMN→NAD⁺) |
| NMNH (UthPeak™) | 3× Higher | Rapid | More Direct |
UthPeak® NMNH completed the world's first, largest, and longest human clinical trial on Reduced NMN — 90 days, 80 healthy participants, Phase I.
UthPeak™ is the world's first commercially available, certified NMNH ingredient. Patent-pending crystalline form for superior stability. 98%+ purity. Suitable for capsules, tablets, and powder formats. Now commercially available outside the lab for the first time — and Age Factory™ was among the first brands to bring it to market.
NMNH is the foundation. Longevity Complete by Age Factory™ layers in 9 more clinically-backed compounds for a full-spectrum daily protocol.
See Longevity Complete by Age Factory™* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Results may vary. Always consult your healthcare provider before starting any new supplement regimen. UthPeak™ is a registered trademark of EffePharm Ltd.